A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Jan 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a new treatment called Vunakizumab for patients with various rheumatic diseases, including ankylosing spondylitis, psoriatic arthritis, and others. The goal is to collect important information about how patients respond to this treatment, their medication patterns, and overall patient experiences. This study is particularly important because there hasn’t been a large-scale study like this in China, and the information gathered will help doctors make better treatment choices for their patients with these conditions.

To participate in this study, individuals need to have a diagnosed rheumatic disease mentioned above and should either be currently receiving or planning to receive the treatment. They must also be able to follow their doctor's instructions and understand the purpose of the study. Participants will be expected to keep track of their health and treatment experiences over time. It’s essential to know that this study is not yet recruiting participants, but it will be a valuable opportunity for those who meet the criteria to contribute to important research in rheumatology.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed with rheumatic autoimmune diseases such as ankylosing spondylitis/radiologically negative axial spondyloarthritis/psoriatic arthritis/polymyalgia rheumatica/Takayasu arteritis/giant cell arteritis/ non-ocular Behcet's disease/ enthesitis-related arthritis;
• • 2. Currently receiving or planning to receive fulvezinib treatment;
• • 3. Can follow up according to the doctor's advice;
• • 4. Able to understand and sign the informed consent form, understand the purpose of this study, and voluntarily participate in this study.
• Exclusion Criteria:
• • 1.Investigator believes will prevent the subject from following and completing the study protocol